Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma-Reference-Cited by-同舟云学术

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Published:2015-02-03 Issue:1 Volume:14 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Atefi Mohammad,Titz Bjoern,Avramis Earl,Ng Charles,Wong Deborah JL,Lassen Amanda,Cerniglia Michael,Escuin-Ordinas Helena,Foulad David,Comin-Anduix Begonya,Graeber Thomas G,Ribas Antoni

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12943-015-0293-5.pdf

Reference28 articles.

1. Jakob JA, Bassett Jr RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23.

2. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–9.

3. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012;18(8):2326–35.

4. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2013;32(19):2373–9.

5. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20(2):183–9.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12

2. Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches;American Society of Clinical Oncology Educational Book;2024-06

3. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines;Genes;2024-02-03

4. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms;International Journal of Cancer;2023-12-11

5. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma;Cancers;2023-11-22